| Market value | 2.21M |
| Price to earnings (P/E) | Not meaningful (loss) |
| Price to book | 0.2 |
| Free cash flow yield | -257.5% |
| Net income | -18.86M |
| Return on equity | -200.6% |
| Return on assets | -147.6% |
| Cash and equivalents | 832.0K |
| Current ratio | 2.55 |
| EPS, diluted (last 12 months) | -1.58 |
| Shares outstanding | 6.33M |
| Dividends paid (last 12 months) | None |
| Price | 0.6303 |
| 52-week high | 52.50 |
| 52-week low | 0.5600 |
| 1-year price change | -98.62% |
| Average volume (3 months) | 2.74M |
| Beta against the S&P 500 (1 year) | 2.80 |
Calculated from Propanc Biopharma, Inc.'s SEC filings (latest quarter ending Jun 30, 2026) and the price above. "Last 12 months" adds up the four most recent quarters. Beta compares one year of daily returns with the S&P 500 (SPY). Dividends from Polygon.io or Nasdaq.